IL18 and colitis: Inhibition or knockdown of the NLRP3 inflammasome could alleviate the severity of DSS-induced colitis, control the release of IL-1β and IL-18, and suppress the inflammatory response of UC (Kelley et al., 2019; Lv et al., 2021).